Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

SSRIs and placental dysfunction.

Banga A, Handratta V, Ibrahim L, Connor DF.

Med Hypotheses. 2011 Aug;77(2):311-2. doi: 10.1016/j.mehy.2011.05.023. Epub 2011 Jun 12. No abstract available.

PMID:
21664765
2.

Neuroimaging findings and brain-behavioral correlates in a former boxer with chronic traumatic brain injury.

Handratta V, Hsu E, Vento J, Yang C, Tanev K.

Neurocase. 2010 Apr;16(2):125-34. doi: 10.1080/13554790903329166. Epub 2009 Dec 4.

PMID:
19967598
3.

Desvenlafaxine succinate for major depressive disorder: a critical review of the evidence.

Kamath J, Handratta V.

Expert Rev Neurother. 2008 Dec;8(12):1787-97. doi: 10.1586/14737175.8.12.1787. Review.

PMID:
19086875
4.

Murine toxicology and pharmacokinetics of novel retinoic acid metabolism blocking agents.

Patel JB, Khandelwal A, Chopra P, Handratta VD, Njar VC.

Cancer Chemother Pharmacol. 2007 Nov;60(6):899-905. Epub 2007 Mar 8.

PMID:
17345084
5.

Regulation of androgen receptor activity by tyrosine phosphorylation.

Guo Z, Dai B, Jiang T, Xu K, Xie Y, Kim O, Nesheiwat I, Kong X, Melamed J, Handratta VD, Njar VC, Brodie AM, Yu LR, Veenstra TD, Chen H, Qiu Y.

Cancer Cell. 2006 Oct;10(4):309-19. Erratum in: Cancer Cell. 2007 Jan;11(1):97.

6.

Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model.

Jelovac D, Macedo L, Goloubeva OG, Handratta V, Brodie AM.

Cancer Res. 2005 Jun 15;65(12):5439-44.

7.

Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model.

Handratta VD, Vasaitis TS, Njar VC, Gediya LK, Kataria R, Chopra P, Newman D Jr, Farquhar R, Guo Z, Qiu Y, Brodie AM.

J Med Chem. 2005 Apr 21;48(8):2972-84.

PMID:
15828836
8.

Novel retinoic acid metabolism blocking agents endowed with multiple biological activities are efficient growth inhibitors of human breast and prostate cancer cells in vitro and a human breast tumor xenograft in nude mice.

Patel JB, Huynh CK, Handratta VD, Gediya LK, Brodie AM, Goloubeva OG, Clement OO, Nanne IP, Soprano DR, Njar VC.

J Med Chem. 2004 Dec 30;47(27):6716-29.

PMID:
15615521
9.

Potent CYP17 inhibitors: improved syntheses, pharmacokinetics and anti-tumor activity in the LNCaP human prostate cancer model.

Handratta VD, Jelovac D, Long BJ, Kataria R, Nnane IP, Njar VC, Brodie AM.

J Steroid Biochem Mol Biol. 2004 Oct;92(3):155-65.

PMID:
15555909
10.

Effects of exemestane and tamoxifen in a postmenopausal breast cancer model.

Jelovac D, Macedo L, Handratta V, Long BJ, Goloubeva OG, Ingle JN, Brodie AM.

Clin Cancer Res. 2004 Nov 1;10(21):7375-81.

11.

Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model.

Long BJ, Jelovac D, Handratta V, Thiantanawat A, MacPherson N, Ragaz J, Goloubeva OG, Brodie AM.

J Natl Cancer Inst. 2004 Mar 17;96(6):456-65.

PMID:
15026471
12.

Novel P450(17alpha) inhibitors: 17-(2'-oxazolyl)- and 17-(2'-thiazolyl)-androstene derivatives.

Zhu N, Ling Y, Lei X, Handratta V, Brodie AM.

Steroids. 2003 Sep;68(7-8):603-11.

PMID:
12957665
13.

Three dimensional pharmacophore modeling of human CYP17 inhibitors. Potential agents for prostate cancer therapy.

Clement OO, Freeman CM, Hartmann RW, Handratta VD, Vasaitis TS, Brodie AM, Njar VC.

J Med Chem. 2003 Jun 5;46(12):2345-51.

PMID:
12773039

Supplemental Content

Loading ...
Support Center